NLE Cardiovascular Nursing — Heart Failure and Cardiac DysrhythmiasSummary

Heart failure is defined as the clinical syndrome in which the heart is unable to pump enough blood to meet the metabolic demands of the body. It is not a single disease entity but rather the end result of various conditions that damage or overwork the myocardium. The underlying etiologies include coronary artery disease (the most common cause globally), acute myocardial infarction, systemic hypertension, valvular disease (mitral stenosis, aortic stenosis, chronic regurgitation), dilated cardiomyopathy, restrictive cardiomyopathy, and high-output states (thyrotoxicosis, anemia, pregnancy). In the Philippine context, hypertension-related HF and ischemic heart disease secondary to smoking, diabetes, and metabolic syndrome are prevalent.

The body initially compensates for reduced cardiac output through three major mechanisms: (1) Sympathetic nervous system activation increases heart rate and contractility, attempting to maintain cardiac output through the Frank-Starling mechanism (increased preload increases contractility). (2) The renin-angiotensin-aldosterone system (RAAS) is activated, causing sodium and water retention to increase circulating volume and preload. (3) Ventricular hypertrophy (thickening of the wall) and dilation (enlargement of the chamber) occur to improve contractility. Over time, these compensatory mechanisms become maladaptive: increased sympathetic activity causes vasoconstriction and tachycardia, increasing afterload and myocardial oxygen demand; excessive RAAS activation causes fluid overload, pulmonary and systemic congestion, and neurohormonal activation; and chronic ventricular remodeling leads to chamber dysfunction and further deterioration. This pathophysiology explains why HF treatment blocks these very systems—using beta-blockers to reduce sympathetic drive, ACE inhibitors and ARBs to block RAAS, and diuretics to reduce fluid overload.

In left-sided HF, the left ventricle fails to pump effectively, causing blood to back up into the pulmonary circulation. The mnemonic 'left = lungs' helps recall that left HF presents with pulmonary manifestations. Clinical manifestations result from pulmonary vascular congestion: dyspnea (shortness of breath at rest or with exertion), orthopnea (inability to breathe when lying flat, requiring multiple pillows), and paroxysmal nocturnal dyspnea (sudden breathlessness at night, often forcing the patient to sit upright). Physical examination findings include crackles or rales on lung auscultation (particularly at the bases), a persistent dry or productive cough, and in acute pulmonary edema, pink or blood-tinged (frothy) sputum indicating alveolar fluid. The patient appears fatigued and anxious, with tachycardia, tachypnea, and an S3 ventricular gallop on cardiac auscultation. The ejection fraction is typically reduced (less than 40%), indicating systolic dysfunction, though diastolic dysfunction (preserved ejection fraction with impaired relaxation) also causes left HF symptoms.

In right-sided HF, the right ventricle fails to pump blood effectively into the pulmonary circulation, causing blood to back up into the systemic venous circulation. The mnemonic 'right = rest of the body' helps recall that right HF presents with systemic manifestations. Clinical manifestations result from venous congestion: peripheral and dependent edema (pitting edema in the lower extremities and sacrum when bedridden), weight gain from fluid retention, jugular venous distention (JVD) visible even when the head of the bed is elevated, hepatomegaly (enlarged liver, palpable below the right costal margin) and ascites (fluid in the peritoneal cavity) indicating hepatic congestion, and right upper quadrant pain or tenderness from stretching of the liver capsule. Gastrointestinal congestion causes anorexia, nausea, and hepatic dysfunction. The most common cause of right HF in clinical practice is left HF itself (right HF secondary to increased pulmonary pressures from left-sided disease); other causes include chronic lung disease (COPD, pulmonary hypertension), pulmonary embolism, and right ventricular infarction.

Acute pulmonary edema is a life-threatening condition in which fluid rapidly accumulates in the alveoli, severely impairing gas exchange and oxygenation. It typically results from acute decompensated left HF, acute myocardial infarction with sudden loss of left ventricular function, or acute mitral regurgitation. The patient presents in extreme distress: severe dyspnea, orthopnea, air hunger, anxiety, pallor, cyanosis, and in advanced cases, altered consciousness. The characteristic finding is pink, frothy sputum (foam-like, blood-tinged fluid in the airway) reflecting pulmonary edema mixed with blood. Auscultation reveals crackles throughout all lung fields. The patient is tachycardic, tachypneic, and hypoxic with low oxygen saturation. This is a medical emergency requiring immediate intervention to restore oxygenation and reduce preload. The nursing priority acronym LMNOP guides management: (L) High Fowler's position with legs dependent—gravity reduces venous return and improves oxygenation; (M) Morphine intravenously to reduce anxiety, dilate vessels, and reduce the work of breathing; (N) Nitrates (intravenous nitroglycerin) to cause venodilation and reduce preload; (O) Oxygen via high-flow methods (non-rebreather mask, CPAP/BiPAP); (P) Prepare loop diuretics (IV furosemide) to remove fluid rapidly.

Daily weight monitoring is one of the most important self-management tools for patients with chronic HF and is a cornerstone of nursing patient education. Patients are instructed to weigh themselves at the same time each day (preferably in the morning after voiding, before eating or drinking), using the same scale, and in similar clothing. A weight gain of approximately 1 kilogram (about 2 pounds) in a single day or 2.5 kilograms (about 5–6 pounds) in a week indicates fluid retention and potential HF exacerbation, requiring prompt notification of the healthcare provider. This may signal medication non-adherence, dietary salt excess, disease progression, or need for diuretic adjustment. Weight loss may indicate medication overcorrection or other complications. The assessment of daily weight is more specific and sensitive than reliance on subjective symptoms (which patients often miss or deny) and allows early intervention before acute decompensation occurs. In the context of Philippine healthcare, where many patients manage HF in ambulatory or community settings, this self-monitoring skill is critical for preventing hospital admissions and reducing the burden on secondary and tertiary facilities.

Diagnostic evaluation of HF includes several key tests: (1) B-type natriuretic peptide (BNP) is a hormone released by the ventricles in response to stretch and elevated pressure. A BNP level greater than 100 pg/mL (or N-terminal pro-BNP >125 pg/mL) supports the diagnosis of HF, and levels correlate with severity and prognosis; (2) Chest X-ray shows cardiomegaly (enlarged cardiac silhouette with cardiothoracic ratio >50%), pulmonary vascular congestion with bilateral interstitial or alveolar infiltrates, Kerley B lines (horizontal lines at the lung bases indicating pulmonary edema), and pleural effusion; (3) Echocardiography is the gold standard for HF diagnosis, measuring the left ventricular ejection fraction (LVEF), which is the percentage of blood ejected with each beat (normal 55–70%, reduced EF <40% indicates systolic HF, preserved EF ≥50% indicates diastolic HF or HF with preserved ejection fraction [HFpEF]); (4) Electrocardiogram may show left ventricular hypertrophy, previous infarction, or dysrhythmias; (5) Complete blood count, comprehensive metabolic panel, and troponin help identify causes (anemia, renal dysfunction, acute ischemia) and guide therapy; (6) Plasma natriuretic peptides have prognostic value and guide therapy escalation.

Cardiac dysrhythmias (also called arrhythmias) are disturbances in the rate, rhythm, or conduction of the heartbeat. The key principle is that dysrhythmias must be assessed not in isolation but in context of the patient's hemodynamic response: a dysrhythmia matters clinically if it compromises cardiac output (blood pressure, perfusion, consciousness) or increases myocardial oxygen demand beyond the coronary blood supply. Dysrhythmias are classified by site of origin (supraventricular/atrial, nodal, or ventricular) and by rate effect (bradycardia <60 bpm, tachycardia >100 bpm, or normal 60–100 bpm). Pathophysiology includes altered automaticity (ectopic pacemakers firing faster than the SA node), triggered activity (afterdepolarizations), and reentry (circus movement of impulses around anatomical or functional barriers). Clinical significance depends on factors: Is there hemodynamic compromise (hypotension, altered consciousness, chest pain, dyspnea)? Is oxygenation maintained? How long has the dysrhythmia been present? Are there underlying cardiac or pulmonary diseases? Stable dysrhythmias may require only observation and treatment of the cause, while unstable dysrhythmias may require immediate cardioversion or defibrillation.

Sinus bradycardia is a regular rhythm originating from the SA node with a rate less than 60 beats per minute. Normal sinus bradycardia is common in trained athletes (up to 40 bpm). Pathological sinus bradycardia may result from SA node disease, increased vagal tone, hypothyroidism, myocardial infarction (especially inferior), medications (beta-blockers, calcium channel blockers, digoxin), or hyperkalemia. Clinical manifestations depend on severity: mild bradycardia may be asymptomatic, while significant bradycardia can cause dizziness, syncope, fatigue, hypotension, and decreased cardiac output. Treatment is necessary only if the patient is symptomatic; the drug of choice is atropine (a parasympatholytic agent that blocks vagal effects and increases heart rate). If atropine is ineffective or recurrent symptoms occur, a temporary or permanent pacemaker may be inserted. Sinus tachycardia is a regular rhythm from the SA node with a rate greater than 100 bpm, representing a normal compensatory response to physiological stress: fever, pain, anxiety, hypovolemia, hypoxia, anemia, exercise, or thyrotoxicosis. Sinus tachycardia itself is not treated; instead, the underlying cause is treated (antipyretics for fever, analgesics for pain, fluid resuscitation for hypovolemia, oxygen for hypoxia). If the cause is not identified and corrected, persistent tachycardia will continue.

Atrial fibrillation (AFib) is the most common chronic dysrhythmia encountered in clinical practice, affecting millions worldwide and becoming increasingly prevalent with age, hypertension, heart disease, and in the Philippines, especially with uncontrolled hypertension and valvular disease (rheumatic heart disease). In AFib, the atria fire rapidly and chaotically (at rates of 350–600 bpm) rather than in an organized, coordinated manner. The SA node loses control, and multiple foci in the atria generate impulses. On the ECG, there are no visible P waves (the chaotic atrial activity creates an undulating baseline called 'fibrillatory waves' or 'f waves'), and the ventricular response is irregularly irregular (no two R-R intervals are the same), with rates often between 80–200 bpm depending on AV nodal conduction and any rate-control medications. AFib has two major clinical consequences: (1) Loss of the atrial 'kick'—the normal atrial contraction contributes about 30% of ventricular filling; without it, cardiac output decreases and diastolic function is impaired. (2) Stasis of blood in the atrial appendage (where blood pools due to lack of organized atrial contraction) creates a high risk of thrombus formation, potentially leading to embolic stroke (patients with AFib have a 4–5 fold increased risk of stroke). Because of this stroke risk, anticoagulation is essential in most AFib patients, using warfarin (target INR 2–3) or direct oral anticoagulants (DOACs) like dabigatran, apixaban, or rivaroxaban. The CHA₂DS₂-VASc score is used to assess stroke risk and guide anticoagulation decisions.

Atrial flutter is a rapid, regular atrial dysrhythmia in which the atria contract at a very fast rate, typically 250–350 bpm. On the ECG, a characteristic 'sawtooth' or 'picket fence' pattern of flutter waves (F waves) appears, representing the regular, repetitive atrial depolarization. The ventricular response may be regular or irregular depending on the AV node's conduction pattern. Atrial flutter often occurs in patients with underlying heart disease, chronic lung disease, or after cardiac surgery. While atrial flutter itself is less common than AFib, it carries similar risks: loss of atrial kick, decreased cardiac output, and potential for thrombus formation. Management focuses on rate control (slowing the ventricular response with medications like beta-blockers or digoxin) or rhythm control (restoring sinus rhythm with antidysrhythmic drugs or electrical cardioversion).

Ventricular dysrhythmias originate below the AV node and include premature ventricular contractions (PVCs), ventricular tachycardia (VT), and ventricular fibrillation (VF). Premature ventricular contractions are early beats originating in the ventricles; on the ECG, they appear as wide QRS complexes (>0.12 seconds) without preceding P waves, followed by a compensatory pause. PVCs are common and often benign in patients without underlying heart disease, but in post-MI patients or those with structural heart disease, they may signal increased risk of malignant dysrhythmias. Frequent PVCs (>6 per minute, multifocal, or occurring in runs) may require suppression with antidysrhythmic medications. Ventricular tachycardia is defined as a run of three or more ventricular beats at a rapid rate (usually >100 bpm), appearing as wide QRS complexes on the ECG. VT can be sustained (lasting >30 seconds, often requiring intervention) or nonsustained (brief, self-terminating). Pulseless ventricular tachycardia (no perfusing rhythm despite electrical activity) is a cardiac arrest rhythm requiring immediate CPR and defibrillation. Ventricular tachycardia with a pulse but hemodynamic instability (hypotension, altered consciousness, chest pain) requires urgent synchronized cardioversion. VT with a pulse and stable hemodynamics may be treated with IV antidysrhythmic medications (amiodarone, lidocaine, procainamide). Ventricular fibrillation is a chaotic, completely disorganized ventricular activity where the ventricles quiver ineffectively, producing no coordinated contraction and no cardiac output—it is essentially mechanical and electrical cardiac arrest. On the ECG, VF appears as a wavy, undulating baseline with no discernible QRS complexes. VF is immediately life-threatening and is the most common initial rhythm in sudden cardiac death from acute MI. The only definitive treatment is immediate defibrillation (unsynchronized shock), combined with CPR and IV epinephrine. Without rapid defibrillation (within minutes), VF degenerates to asystole, and survival is extremely poor.

Asystole, also called 'flatline,' is the complete absence of electrical activity in the heart—no P waves, no QRS complexes, no T waves, just a straight line on the ECM. Asystole indicates severe myocardial depression and is a terminal rhythm with extremely poor prognosis. Causes include prolonged cardiac arrest, severe myocardial damage, profound hypoxia, or severe hyperkalemia. Asystole may be primary (occurring as the initial rhythm in cardiac arrest) or secondary (occurring after degeneration of another rhythm such as VF). The key point: asystole is not a shockable rhythm (defibrillation will not restart the heart). Management of asystole includes continuous CPR, airway management with intubation, IV access, and administration of epinephrine every 3–5 minutes according to ACLS protocols. Some experts recommend a trial of high-dose epinephrine and atropine (to block vagal effects and increase heart rate), but evidence for improved outcomes is weak. The prognosis of asystole, particularly if the rhythm persists after 20–30 minutes of resuscitation, is very poor, and many guidelines suggest considering termination of resuscitation efforts in specific circumstances.

These are two distinct electrical therapies for dysrhythmias and must not be confused. Defibrillation is an unsynchronized electrical shock delivered to a patient in cardiac arrest (pulseless) with a shockable rhythm (ventricular fibrillation or pulseless ventricular tachycardia). The shock is delivered immediately without regard to the cardiac cycle—the goal is to depolarize all myocardial cells simultaneously and stop the chaotic activity, allowing the heart's electrical system to reset and resume organized, perfusing rhythms. Defibrillation is a true emergency intervention, performed immediately per ACLS protocols, ideally within 3 minutes of cardiac collapse. Modern defibrillators are automated external defibrillators (AEDs) that analyze the rhythm, recognize shockable rhythms, and prompt the operator. Defibrillation causes no pain or hemodynamic consequences because the patient is already in cardiac arrest. In contrast, synchronized cardioversion is a timed electrical shock delivered to a conscious or semiconscious patient (with a pulse) who has an unstable dysrhythmia such as atrial fibrillation with rapid ventricular response, unstable atrial flutter, or stable ventricular tachycardia. The shock is synchronized to occur during the QRS complex (avoiding the vulnerable T wave period, which would risk inducing VF). The patient must be sedated and analgesia provided (with medications like midazolam and fentanyl) because synchronized cardioversion is painful. After cardioversion, the patient's rhythm, vital signs, and level of consciousness are reassessed.

A pacemaker is an electronic device that delivers timed electrical impulses to stimulate the heart to contract when the patient's own conduction system fails. Indications for pacemaker insertion include symptomatic bradycardia (heart rate <60 bpm with symptoms such as syncope or hypotension), advanced heart block (third-degree block where no atrial impulses reach the ventricles), and sometimes atrial fibrillation with a very slow ventricular response. Pacemakers may be temporary or permanent. Temporary pacemakers include transcutaneous (external pads on the chest connected to an external pulse generator—used emergently to quickly restore a perfusing rhythm) and transvenous (a wire advanced via a central vein to the right atrium or ventricle, connected to an external generator—used when temporary pacing is needed for several hours to days). Permanent pacemakers are surgically implanted under the clavicle (usually on the left side), with leads tunneled through a vein to the atrium and/or ventricle. The generator is placed subcutaneously and is powered by a lithium battery lasting 5–10 years. Most modern pacemakers are dual-chamber (atrial and ventricular) or single-chamber (ventricular only), and many have rate-responsiveness features that increase pacing rate with patient activity. Nursing assessment focuses on ECG findings: the pacemaker should show a pacing spike (a small vertical line on the ECG) followed by a QRS complex (ventricular capture) or a P wave (atrial capture), demonstrating that the pacing impulse triggered a myocardial contraction. Two important failure modes must be monitored: (1) Failure to capture—a pacing spike is present but no QRS or P wave follows, indicating the electrical impulse did not trigger contraction and the patient may have hemodynamic compromise; (2) Failure to sense—the pacemaker fails to recognize the patient's own heartbeat and fires inappropriately (e.g., firing during or immediately after a spontaneous QRS, creating dangerous competition between the device and the patient's intrinsic rhythm). After pacemaker implantation, the patient must restrict movement of the affected arm to prevent lead dislodgement. Patient education includes: checking the pulse daily (should match or exceed the pacemaker's set rate) and reporting rates below the set rate, which might indicate battery depletion; reporting dizziness, syncope, or hiccups (hiccups can indicate lead displacement or pacemaker malfunction); avoiding strong electromagnetic fields (MRI is contraindicated unless the device is specifically MRI-conditional or compatible), arc welding, and powerful magnets; understanding that most household appliances and cell phones are safe if kept a short distance from the device; carrying a pacemaker identification card; and attending regular follow-up appointments for device checks.

Digoxin (also called digitalis glycoside or cardiac glycoside) is a medication derived from the digitalis plant (foxglove) that has been used for heart failure and dysrhythmia management for over 200 years. Digoxin has two main effects on the heart: (1) Positive inotropic effect—digoxin binds to and inhibits the Na+/K+-ATPase pump in myocardial cell membranes, increasing intracellular calcium, which strengthens myocardial contraction (improves contractility). This is beneficial in systolic heart failure by increasing the force of each beat and improving cardiac output. (2) Negative chronotropic effect—digoxin increases vagal tone and slows conduction through the AV node, decreasing the heart rate. This is beneficial in atrial fibrillation, where rapid ventricular rates reduce diastolic filling time and worsen hemodynamics; slowing the rate with digoxin allows longer diastolic filling and improves cardiac output. The therapeutic serum level of digoxin is 0.5–2.0 ng/mL. Levels above 2 ng/mL indicate toxicity. The therapeutic window is narrow (the toxic level is close to the therapeutic level), so careful monitoring is essential. Before administering digoxin, the nurse must take the apical pulse (by auscultation over the apex of the heart, not the radial pulse) for a full minute. If the apical rate is below 60 bpm in an adult (or below 90–110 bpm in infants), the dose should be held and the healthcare provider notified. This is because digoxin slows conduction and can cause dangerous bradycardia or AV block at toxic levels. Hypokalemia (low potassium) greatly increases the risk of digoxin toxicity: potassium normally competes with digoxin for binding sites on the Na+/K+-ATPase pump. When potassium is low, there is less competition, so more digoxin binds and accumulates intracellularly, increasing toxicity. For this reason, patients on digoxin should have potassium levels monitored regularly, especially if they are also taking diuretics (which cause potassium loss). Signs of digoxin toxicity include GI symptoms (anorexia, nausea, vomiting), neurological symptoms (weakness, headache, confusion), visual disturbances (blurred vision, yellow-green halos around lights—a classic sign called xanthopsia), and dysrhythmias (PVCs, bradycardia, AV block, and in severe toxicity, ventricular dysrhythmias). If toxicity is suspected, digoxin levels are drawn (therapeutic range 0.5–2 ng/mL; toxicity likely if >2 ng/mL), and the drug is held. The specific antidote for digoxin toxicity is digoxin immune Fab (also called Digibind or DigiFab), which are fragments of antibodies that bind to digoxin, inactivate it, and allow it to be renally excreted.

Diuretics are medications that increase urine output and sodium excretion, reducing circulating blood volume and preload, thereby decreasing pulmonary and systemic congestion in heart failure. Loop diuretics (such as furosemide, torsemide, bumetanide) act on the thick ascending limb of the loop of Henle, blocking the Na+/K+/2Cl- cotransporter and preventing reabsorption of sodium. Loop diuretics are the most potent diuretics, producing rapid, significant fluid loss, and are the first-line diuretics for HF with congestion and for acute pulmonary edema. IV furosemide is used emergently in acute pulmonary edema, with onset within minutes and duration of 1–2 hours. Oral furosemide is used for chronic HF management. Thiazide diuretics (such as hydrochlorothiazide, chlorthalidone) act on the distal convoluted tubule and are less potent than loop diuretics; they are used for mild HF and hypertension. Both loop and thiazide diuretics cause significant potassium loss (hypokalemia) because the increased sodium delivery to the collecting duct increases sodium reabsorption coupled with potassium and hydrogen ion secretion. Hypokalemia is dangerous: it causes muscle weakness, fatigue, dysrhythmias (especially premature contractions and VT), and as mentioned earlier, greatly increases the risk of digoxin toxicity in patients taking both drugs. For this reason, patients on loop or thiazide diuretics should have potassium levels monitored regularly (normal 3.5–5.0 mEq/L), and often a potassium-sparing diuretic or potassium supplement is added. Important nursing considerations: When giving IV furosemide, it should be infused slowly (not as a rapid IV push) because rapid infusion increases the risk of ototoxicity (hearing loss), which is irreversible. Daily weights must be monitored to assess fluid loss; weights should not decrease too rapidly (more than 1–2 kg per day is excessive and may lead to acute kidney injury and electrolyte abnormalities). Ongoing assessment of fluid status, potassium levels, kidney function (creatinine, BUN), and signs of dehydration is essential.

Potassium-sparing diuretics include spironolactone (an aldosterone antagonist), amiloride, and triamterene. Spironolactone is particularly important in HF management because it blocks aldosterone, a hormone of the renin-angiotensin-aldosterone system that promotes sodium reabsorption and potassium excretion in the collecting duct. By blocking aldosterone, spironolactone promotes sodium and water excretion while conserving potassium. Beyond its diuretic effect, spironolactone has been shown in landmark clinical trials to improve survival in HF, reduce hospitalizations, and slow disease progression. This is not merely a symptomatic benefit but a disease-modifying effect. Spironolactone also has vasodilatory and anti-fibrotic effects that contribute to improved cardiac remodeling and function. However, because potassium-sparing diuretics conserve potassium, the major risk is hyperkalemia (elevated serum potassium), which is dangerous and can cause life-threatening dysrhythmias. For this reason, patients on spironolactone must have potassium levels monitored closely (especially when the drug is initiated), and potassium supplements and high-potassium foods should be avoided unless specifically prescribed. ACE inhibitors and ARBs (discussed below) also increase potassium by reducing aldosterone, so combining these with spironolactone requires careful monitoring. Patients with renal insufficiency have increased risk of hyperkalemia on spironolactone.

ACE inhibitors (such as enalapril, lisinopril, ramipril) and angiotensin II receptor blockers or ARBs (such as losartan, valsartan, candesartan) are medications that block the renin-angiotensin-aldosterone system (RAAS) at different points. ACE inhibitors block angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor and sodium-retaining hormone). ARBs directly block the angiotensin II type 1 receptor, preventing angiotensin II's effects. Both classes achieve similar beneficial effects in HF: (1) Vasodilation—reduced angiotensin II causes venous and arterial dilation, reducing preload and afterload and decreasing the workload on the failing heart; (2) Reduced cardiac remodeling—chronic angiotensin II promotes myocardial fibrosis and adverse remodeling; blocking RAAS reduces these effects and may prevent disease progression; (3) Improved survival—multiple landmark trials have demonstrated that ACE inhibitors and ARBs improve survival in systolic HF, reduce hospitalizations, and slow progression to end-stage disease. These are cornerstone therapies in modern HF management. Side effects of ACE inhibitors include: dry cough (occurs in 5–10% of patients, a direct effect of angiotensin-converting enzyme inhibition and accumulation of bradykinin, which stimulates cough receptors), hyperkalemia (because angiotensin II normally promotes aldosterone, reducing it conserves potassium), hypotension (especially orthostatic hypotension, requiring caution with concurrent diuretics), angioedema (rare but serious, swelling of the lips, tongue, or airway—requires immediate discontinuation and emergency treatment), and worsening of renal function in patients with severe renal disease. Monitoring includes checking potassium levels (especially when initiating therapy), renal function (creatinine, BUN), and blood pressure. If a patient on an ACE inhibitor develops a dry cough and it is intolerable, an ARB may be substituted (ARBs rarely cause cough). ARBs carry similar risks (hyperkalemia, hypotension, worsening renal function) but do not cause the characteristic dry cough.

Beta-blockers (such as carvedilol, metoprolol succinate, and bisoprolol) are medications that block the effects of sympathetic stimulation on the heart. The sympathetic nervous system normally increases heart rate and contractility in response to stress. In HF, chronic sympathetic activation is maladaptive: it increases heart rate, contractility, vasoconstriction, and myocardial oxygen demand, worsening the condition and promoting progression. Beta-blockers counter these harmful effects and have been shown in multiple landmark trials to improve survival in systolic HF, reduce hospitalizations, and slow disease progression—they are now considered cornerstone therapy. However, beta-blockers are started at very low doses and titrated slowly (sometimes over weeks to months) because initial doses can cause acute worsening of HF by reducing contractility. The strategy is 'start low, go slow'—beginning with doses such as carvedilol 3.125 mg twice daily and gradually increasing every 2–4 weeks toward target doses (such as carvedilol 25 mg twice daily). Patients must be educated that they may initially feel worse or more fatigued when starting beta-blockers; this is temporary and improves as the body adapts and the heart remodels positively. Critical nursing precautions: (1) Hold a beta-blocker dose if the heart rate is below 60 bpm or if the patient is hypotensive; (2) Never abruptly stop a beta-blocker—sudden discontinuation causes a 'rebound' effect where sympathetic activity surges, causing tachycardia, hypertension, angina, and potentially fatal dysrhythmias. If a beta-blocker must be discontinued, it should be tapered slowly over days to weeks; (3) Use caution in patients with bradycardia, AV block, asthma/COPD (beta-2 antagonism can cause bronchoconstriction), or severe peripheral vascular disease.

Nitrates (such as isosorbide dinitrate, isosorbide mononitrate, and IV nitroglycerin) are medications that cause direct smooth muscle relaxation in blood vessels, with a predominant effect on veins. By dilating veins, nitrates reduce venous return and left ventricular preload—the amount of stretch on the left ventricle—decreasing the volume of blood the ventricle must pump. This is particularly beneficial in HF and pulmonary edema because reducing preload relieves congestion and improves breathing without significantly reducing cardiac output (which depends more on contractility and afterload than on preload in the HF patient). Nitrates are used acutely (IV nitroglycerin in pulmonary edema) and chronically (oral isosorbide for symptom relief). Side effects include headache (very common, caused by vasodilation and increased intracranial pressure—often improves with continued use and can be managed with acetaminophen), orthostatic hypotension (dizziness upon standing, especially in the morning—patients are advised to lie down if dizziness occurs and to change positions slowly), and rarely, reflex tachycardia or angina. An important concept: nitrate tolerance can develop with continuous exposure; to prevent tolerance, a nitrate-free interval of 10–14 hours per day is recommended (e.g., taking the dose only during the day, with an off-period at night). Hydralazine is a direct arterial vasodilator that reduces afterload (the resistance against which the left ventricle must pump). By reducing afterload, hydralazine decreases the workload on the failing ventricle and may improve ejection fraction. In a landmark trial (the V-HeFT trial), the combination of hydralazine and isosorbide dinitrate improved survival in HF patients, particularly in African Americans. This combination therapy is now considered appropriate for certain HF populations, particularly those intolerant of ACE inhibitors or ARBs. Monitoring includes assessment of blood pressure (hold if systolic BP is very low, typically <90 mmHg), signs of hypotension or reflex tachycardia, and in long-term nitrate use, assessment for tolerance.

Antidysrhythmic medications are classified by their mechanism (Vaughan-Williams classification): Class I (sodium channel blockers like flecainide, procainamide, quinidine), Class II (beta-blockers), Class III (potassium channel blockers like amiodarone, sotalol), and Class IV (calcium channel blockers). Of these, amiodarone is one of the most commonly used in clinical practice because of its effectiveness in both atrial and ventricular dysrhythmias and its relative safety in HF patients. Amiodarone has properties of all four classes: it blocks sodium, beta, potassium, and calcium channels, making it a broad-spectrum antidysrhythmic. Amiodarone is used for atrial fibrillation (both acute conversion to sinus rhythm and chronic rate control), for prevention of ventricular dysrhythmias in post-MI patients, and for prevention of sudden cardiac death in HF. However, amiodarone has significant side effects and requires careful monitoring: (1) Pulmonary toxicity—amiodarone can cause pulmonary fibrosis and pneumonitis, which may be irreversible. Patients require baseline and periodic chest X-rays and pulmonary function tests; (2) Thyroid dysfunction—amiodarone is very high in iodine content and can cause both hyperthyroidism and hypothyroidism. Thyroid function (TSH, free T4) should be monitored at baseline and periodically; (3) QT prolongation—amiodarone can prolong the QT interval, increasing the risk of torsades de pointes, a polymorphic VT. However, amiodarone rarely causes torsades despite QT prolongation, possibly because of its other electrophysiological properties; (4) Hepatotoxicity—amiodarone can cause hepatitis and cirrhosis with chronic use; liver function tests require monitoring; (5) Photosensitivity—amiodarone causes increased sensitivity to sunlight, so patients should use strong sunscreen; (6) Drug interactions—amiodarone is highly protein-bound and metabolized by the liver, so it interacts with many drugs, increasing their levels and toxicity. IV amiodarone is used in the acute care setting for unstable VT or recurrent VF not responsive to defibrillation and CPR. Oral amiodarone is used for chronic suppression of dysrhythmias.

Because atrial fibrillation carries a high risk of thromboembolism and stroke due to blood stasis in the atrial appendage, anticoagulation is a cornerstone of AFib management. The CHA₂DS₂-VASc score is used to assess stroke risk: one point each for congestive heart failure, hypertension, age ≥75 (two points if age ≥75), diabetes mellitus, and stroke/TIA/thromboembolism (two points); one point each for vascular disease (prior MI, peripheral artery disease, or aortic plaque), age 65–74, and female sex. Patients with a CHA₂DS₂-VASc score of ≥2 in men or ≥3 in women are recommended to receive anticoagulation. Warfarin (Coumarin) is a vitamin K antagonist that inhibits the synthesis of clotting factors II, VII, IX, and X. Warfarin is effective for stroke prevention in AFib, but it requires INR monitoring (target INR 2–3 for AFib, meaning the prothrombin time is 2–3 times the normal reference value). Monitoring is frequent initially (weekly or more often) and then monthly once stable. Warfarin has a narrow therapeutic window (too low INR means inadequate anticoagulation and stroke risk; too high INR means bleeding risk), and it interacts with many foods (high vitamin K foods like green leafy vegetables reduce warfarin's effect and should be consumed consistently, not variably) and medications. Patient teaching includes: never skip doses, maintain consistent diet, avoid NSAIDs (which increase bleeding risk), report bleeding (spontaneous bruising, blood in stool or urine, nosebleeds), keep INR appointments, and wear medical alert identification. Direct oral anticoagulants (DOACs), also called novel oral anticoagulants (NOACs), include dabigatran (direct thrombin inhibitor), apixaban, rivaroxaban, and edoxaban (factor Xa inhibitors). DOACs have fixed dosing (no INR monitoring needed), fewer drug interactions, faster onset, and reversibility with specific antidotes. Large clinical trials have shown DOACs to be non-inferior or superior to warfarin for stroke prevention in AFib, with less intracranial bleeding but possibly more GI bleeding. In many countries, DOACs are now preferred first-line agents, but cost and availability vary. In the Philippines, warfarin remains widely used due to cost, but DOACs are increasingly available in tertiary centers.

Positive inotropes are medications that increase the force of myocardial contraction (contractility). In acute decompensated HF (acute HF with profound hypotension, severely reduced cardiac output, end-organ hypoperfusion, or cardiogenic shock), when the heart is so damaged that it cannot pump adequately despite diuretics and vasodilators, IV positive inotropes are used to temporarily improve contractility and cardiac output. Dobutamine is a beta-1 adrenergic agonist (sympathomimetic) that increases contractility and heart rate and causes some peripheral vasodilation, improving cardiac output and systemic perfusion. Milrinone is a phosphodiesterase-3 inhibitor that increases intracellular cAMP, increasing contractility (positive inotropic effect) and also causes vasodilation (positive lusitropic effect—improving diastolic function). Both agents are IV infusions used in critical care settings, ideally in an ICU with continuous monitoring. Important considerations: Positive inotropes are NOT disease-modifying; they do not improve long-term HF outcomes and may worsen them by increasing myocardial oxygen demand and promoting dysrhythmias. They are considered temporary bridge therapy to improve acute hemodynamics while underlying causes are addressed (e.g., acute MI, valve rupture, myocarditis) or to improve perfusion while awaiting mechanical support (like an intra-aortic balloon pump) or transplant evaluation. Positive inotropes should be weaned as soon as the acute crisis resolves. Side effects include increased heart rate and myocardial oxygen demand (worsening ischemia), dysrhythmias (premature beats, tachycardia), and tremor (particularly with dobutamine).

Using the NANDA-I (North American Nursing Diagnosis Association-International) framework and the nursing process, common nursing diagnoses for HF and dysrhythmias include: Decreased Cardiac Output related to reduced myocardial contractility or dysrhythmia (Goal: maintain adequate cardiac output as evidenced by stable vital signs, urine output ≥0.5 mL/kg/hr, alert mental status); Excess Fluid Volume related to compensatory mechanisms and sodium/water retention (Goal: achieve euvolemia as evidenced by weight loss, resolution of edema, clear lung sounds); Ineffective Breathing Pattern related to pulmonary congestion (Goal: maintain effective breathing as evidenced by respiratory rate 12–20, SpO₂ >94%, ability to speak in full sentences); Activity Intolerance related to reduced cardiac output and fatigue (Goal: increase activity as tolerated); Ineffective Coping related to chronic disease burden; Deficient Knowledge related to HF self-management; Risk for Infection (particularly if invasive devices present, such as pacemakers or central lines); and Risk for Arrhythmias (acute dysrhythmias). Prioritization follows Maslow's hierarchy: physiological needs (oxygenation, circulation, fluid balance) are highest priority, followed by safety, love/belonging, esteem, and self-actualization. In acute pulmonary edema, the highest priority nursing diagnoses are those related to oxygenation and breathing. In stable chronic HF, priorities shift toward fluid management and self-management education. Nursing interventions are based on the nursing process and include assessment (vital signs, lung sounds, daily weight, I&O, edema assessment), monitoring (ECG, laboratory values, medication administration), positioning (high Fowler's for breathing), activity management, fluid and sodium restriction teaching, medication education, and emotional support.

Comprehensive patient education is essential for HF self-management and prevention of hospitalizations. Key education points include: (1) Daily weight monitoring at the same time each day on the same scale, reporting gains of 1 kg in a day or 2.5 kg in a week; (2) Sodium restriction typically to 2 grams per day (about 1 teaspoon of salt daily)—patients must learn to read food labels for sodium content, avoid processed foods, and use herbs and spices instead of salt; (3) Fluid restriction if prescribed (typically 1.5–2 liters per day), particularly important if severe HF or hyponatremia is present; (4) Medication adherence—never skip doses of ACE inhibitors, ARBs, beta-blockers, or digoxin; understand the purpose of each medication and expected effects; (5) Recognition of HF exacerbation signs: increased dyspnea, orthopnea, weight gain, new or worsening edema, anorexia, nausea, persistent cough, fatigue, confusion; (6) When to seek immediate care: severe dyspnea, chest pain, syncope, severe dizziness, or rapid/irregular pulse; (7) Activity and exercise: balance activity with rest; gradually increase activity as tolerated; avoid strenuous exertion (check with healthcare provider about appropriate activity level); (8) Digoxin safety if taking digoxin: check apical pulse before taking the dose and report if <60 bpm or if experiencing visual disturbances, nausea, or weakness; (9) Pacemaker care if applicable: check pulse daily, avoid electromagnetic interference, carry identification card; (10) Lifestyle modifications: smoking cessation, limit alcohol, maintain healthy weight, control blood pressure and diabetes, manage stress. In the Philippine context, culturally sensitive education that considers common foods, family dynamics, and healthcare access is essential.

Serious complications can develop in HF and dysrhythmia patients: (1) Cardiogenic shock—severe reduction in cardiac output resulting in inadequate tissue perfusion and hypotension (<90 mmHg systolic), requiring emergency interventions including positive inotropes and possibly mechanical circulatory support; (2) Acute pulmonary edema—discussed earlier, a medical emergency with rapid alveolar fluid accumulation; (3) Thromboembolism—blood stasis in dilated atria (particularly in AFib) and ventricles predisposes to thrombus formation, risking stroke, pulmonary embolism, or limb ischemia; (4) Sudden cardiac death—dysrhythmias (particularly VF and pulseless VT) can cause abrupt collapse; implantable cardioverter-defibrillators (ICDs) are devices that detect and treat life-threatening dysrhythmias by delivering a shock; (5) Atrial fibrillation with rapid ventricular response—rate >120–150 bpm causing acute HF decompensation and requiring urgent rate control; (6) Acute kidney injury—HF reduces renal perfusion, worsening renal function and potassium and fluid balance; (7) Hepatic congestion—right HF can cause hepatomegaly, ascites, and hepatic dysfunction; (8) Dysrhythmias—from HF itself or medications such as digoxin or antidysrhythmics; (9) Worsening renal failure—diuretics and ACE inhibitors/ARBs can transiently worsen creatinine, requiring adjustment or cautious monitoring.

The Philippine Nursing Practice Act (Republic Act 9173) defines the scope of nursing practice and requires nurses to provide safe, evidence-based care consistent with Filipino cultural values and healthcare delivery system capabilities. For HF and dysrhythmia management in the Philippines: (1) The Philippine healthcare system has different levels: Level 1 (Barangay Health Station—BHS, with trained barangay health workers), Level 2 (Rural Health Unit—RHU, with nurses and rural health midwives), Level 3 (District Hospital), Level 4 (Provincial/Tertiary Hospital), and Level 5 (Medical Center). Most cardiac diagnostic and interventional procedures (echocardiography, cardiac catheterization, pacemaker insertion) are available only at Level 4–5 facilities; (2) The Department of Health (DOH) PhilPEN (Philippine Health Insurance/PhilHealth) prioritizes NCD prevention and hypertension control at the primary care level (Level 1–2) to prevent HF development and progression. Nurses in BHS and RHU have critical roles in identifying hypertension, promoting medication adherence, and educating on lifestyle modification; (3) RA 9173 mandates that registered nurses provide direct nursing care, health teaching, and advocacy for patients. For HF and dysrhythmias, this includes assessment, patient education, medication administration, monitoring, and coordination of referrals to specialists; (4) Nurses must practice within their scope, recognizing limitations of their facility and arranging referral to higher-level care when appropriate (e.g., referral to a tertiary center for acute pulmonary edema, pacemaker insertion, or advanced HF management); (5) Culturally competent care acknowledges Filipino family structures (extended family decision-making), cultural beliefs about illness, common local foods and their sodium content, and economic constraints affecting medication access and adherence.

The body's initial compensatory responses to reduced cardiac output (sympathetic activation, RAAS activation, ventricular remodeling) become maladaptive over time, worsening HF. Modern HF pharmacology is based on blocking these very mechanisms: beta-blockers reduce sympathetic drive, ACE inhibitors and ARBs block RAAS, diuretics reduce fluid overload, and spironolactone blocks aldosterone. Understanding this relationship explains why HF management seems paradoxical to patients (taking beta-blockers that slow the heart, taking diuretics that remove fluid) and why these drugs improve survival.

In left-sided HF, blood backs up into the lungs, causing progressive pulmonary vascular congestion. Initially, this manifests as dyspnea and crackles (pulmonary edema is present but not life-threatening). As HF worsens acutely, fluid rapidly floods the alveoli, causing acute pulmonary edema—a medical emergency. The nursing interventions for acute pulmonary edema (positioning, oxygen, diuretics, nitrates, morphine) all address the underlying problem of pulmonary congestion and fluid accumulation.

In chronic HF, left-sided failure increases pulmonary pressures, eventually overwhelming the right ventricle, leading to right-sided failure. Thus, chronic HF patients often develop biventricular failure with both pulmonary and systemic congestion. Assessment reveals both left HF signs (orthopnea, crackles) and right HF signs (peripheral edema, JVD, hepatomegaly). This relationship explains why HF affects multiple organs and why comprehensive assessment of both sides is essential.

AFib's chaotic atrial activity causes blood to pool (stasis) in the atria, particularly the atrial appendage, predisposing to thrombus formation. These thrombi can embolize to the brain, causing ischemic stroke. This causal chain directly links the dysrhythmia to stroke risk and explains the absolute necessity of anticoagulation in AFib patients (assessed by CHA₂DS₂-VASc score). Nurses must educate patients that anticoagulation is not optional but essential for stroke prevention, improving medication adherence and outcomes.

Potassium normally competes with digoxin for binding to the Na+/K+-ATPase pump. When potassium is low (hypokalemia), less competition exists, allowing more digoxin to bind intracellularly, increasing myocardial accumulation and toxicity. This is why patients on loop or thiazide diuretics (which cause hypokalemia) and digoxin require careful potassium monitoring. The relationship is critical: low K+ = higher digoxin effect = increased toxicity risk. Conversely, high K+ (hyperkalemia) reduces digoxin binding and effect, potentially leading to subtherapeutic levels.

The treatment of a dysrhythmia depends not only on the type of rhythm but on its hemodynamic consequences. For example, atrial fibrillation with a rate of 80 bpm in a patient with normal blood pressure and no symptoms may require only rate control and anticoagulation; the same AFib in a patient with a rate of 150 bpm and hypotension requires urgent cardioversion. Similarly, ventricular tachycardia with a pulse but stable blood pressure may be treated with antidysrhythmics, while pulseless VT requires immediate defibrillation and CPR. This relationship underscores the principle that dysrhythmias must always be assessed in clinical context.

Daily weight monitoring serves as an early warning system for HF decompensation. Weight gain of 1 kg in a day or 2.5 kg in a week indicates fluid retention from worsening HF, before acute symptoms (dyspnea, orthopnea) develop. Early detection allows timely intervention (diuretic adjustment, medication modification, provider notification) to prevent acute decompensation and hospitalization. This relationship demonstrates how a simple, patient-performed assessment (daily weight) can have major implications for HF outcomes and reduced healthcare burden.

ACE inhibitors and ARBs improve HF outcomes but increase serum potassium by blocking angiotensin II-mediated aldosterone secretion, which normally promotes K+ excretion. When combined with other K+-conserving agents (spironolactone, NSAIDs) or in patients with renal insufficiency, hyperkalemia risk is heightened. This relationship requires nurses to recognize the dual nature of these drugs: they are beneficial for HF survival but need careful monitoring of K+ and renal function. If K+ rises above safe levels (typically >5.5 mEq/L), the drug may need to be held or dose adjusted.

A pacemaker works by delivering electrical impulses that depolarize the myocardium, triggering mechanical contraction. On the ECG, a pacing spike (electrical impulse) should be followed by a QRS complex (ventricular contraction) or P wave (atrial contraction). The presence of this relationship (spike → QRS) is called 'capture' and indicates the pacemaker is functioning. Absence of this relationship (spike without QRS, called 'failure to capture') indicates malfunction. Understanding this relationship allows nurses to assess pacemaker function on ECGs and identify complications early.

A common HF patient receives both diuretics (for fluid removal) and ACE inhibitors/ARBs (for HF survival benefit). These drugs have opposite effects on potassium: diuretics lower K+ (hypokalemia), while ACE-I/ARBs raise K+ (hyperkalemia). The nurse must understand both effects and monitor K+ levels carefully. If K+ drifts down, supplementation or a potassium-sparing diuretic may be added; if K+ drifts up, ACE-I/ARB dose may need reduction. This relationship demonstrates the importance of integrated understanding of HF pharmacology rather than memorizing drugs in isolation.

HF medications have dual timelines: some provide immediate symptom relief (e.g., diuretics quickly reduce fluid and dyspnea), while others provide long-term benefits that may take weeks to months to manifest (e.g., ACE inhibitors, beta-blockers, and spironolactone improve survival but don't quickly relieve symptoms). Patient education must explain this distinction so that patients don't abandon long-term medications because they don't feel an immediate effect, and so they understand that feeling better acutely (symptom control) is different from actually improving the heart's function (disease modification).

Ventricular dysrhythmias (VT, VF) originate in the ventricles and often cause profound reductions in cardiac output because the ventricles are the main pumping chambers. This explains why ventricular dysrhythmias are more immediately life-threatening than atrial dysrhythmias (which still allow some ventricular filling and output). Pulseless VT and VF cause immediate shock and require emergency defibrillation and CPR. This relationship guides the clinical urgency: ventricular dysrhythmias warrant rapid assessment and treatment, while atrial dysrhythmias may allow more time for careful evaluation and rate control.